Lenvatinib Long-Term Responses in Refractory Thyroid Cancer: Our Mono-Institutional Real-Life Experience with the Multidisciplinary Approach and Review of Literature.

Lenvatinib Long-Term Responses in Refractory Thyroid Cancer: Our Mono-Institutional Real-Life Experience with the Multidisciplinary Approach and Review of Literature.
Oncology. 2019 Aug 07;:1-5
Authors: Denaro N, Latina A, Cesario F, Bramardi F, Corrado L, Borretta G, Merlano MC
Abstract
Lenvatinib (LEN) is a multikinase inhibitor with antiangiogenic properties recently approved in radioactive iodine-refractory differentiated thyroid cancer, hepatocellular carcinoma, and renal cell carcinoma in combination with everolimus. LEN-treated patients frequently have adverse events (AEs) that generally require such dose modifications, including drug discontinuation. Hypertension, diarrhea, weight loss, proteinuria, fatigue, and palmar-plantar erythrodysesthesia are reported among the most frequent AEs, often leading to discontinuations or dose modifications. This paper reports a case series focusing on the role of the immediate multidisciplinary approach to manage AEs.
PMID: 31390629 [PubMed - as supplied by publisher]

Source: Oncology - August 6, 2019 Category: Cancer & Oncology Authors: Denaro N, Latina A, Cesario F, Bramardi F, Corrado L, Borretta G, Merlano MC Tags: Oncology Source Type: research